

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10599980
	Filing Date		2007-04-03
	First Named Inventor	Roland REINER	
	Art Unit	1623	
	Examiner Name	Ganapathy KRISHNAN	
	Attorney Docket Number	067802-5008-US	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4352883		1982-10-05	Franklin LIM	
	2	4424208		1984-01-03	Donald G. WALLACE et al.	
	3	4663286		1987-05-05	Wen-Ghiih TSANG et al.	
	4	4806355		1989-02-21	Mattheus F.A. GOOSEN et al.	
	5	5086350		1992-02-04	Sumihiro NISHIHATA	
	6	5318780		1994-06-07	Tacey X. VIEGAS et al.	
	7	5633001		1997-05-27	Bengt AGERUP	
	8	5800829		1998-09-01	Keith E. DIONNE et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599980
Filing Date	2007-04-03
First Named Inventor	Roland REINER
Art Unit	1623
Examiner Name	Ganapathy KRISHNAN
Attorney Docket Number	067802-5008-US

9	5916790		1999-06-29	Karl C. ENEVOLD	
10	5922025		1999-07-13	William G. HUBBARD	
11	6214331	B1	2001-04-10	John W. VANDERHOFF et al.	
12	6264113	B1	2001-06-12	Douglas W. DINGLER	
13	6605294	B2	2003-08-12	Amarpreet S. SAWHNEY	
14	6642363	B1	2003-11-04	David J. MOONEY et al.	
15	7955789	B2	2011-06-07	Yotaro IZUMI et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020022016	A1	2002-02-21	Stephen E. WALSH et al.	
	2	20020151466	A1	2002-10-17	William G. HUBBARD et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10599980
Filing Date		2007-04-03
First Named Inventor	Roland REINER	
Art Unit	1623	
Examiner Name	Ganapathy KRISHNAN	
Attorney Docket Number	067802-5008-US	

3	20050244358	A1	2005-11-03	Elias Humberto Hermida OCHOA	
---	-------------	----	------------	------------------------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0 727 232	EP	A2	1996-08-21	Mentor Corporation		<input type="checkbox"/>
	2	1 312 382	EP	A1	2003-05-21	Micro Therapeutics, Inc.		<input type="checkbox"/>
	3	1991-009119	WO	A1	1991-06-27	Trancel Corporation		<input type="checkbox"/>
	4	1993-016111	WO	A1	1993-08-19	Ulrich ZIMMERMANN et al.		<input type="checkbox"/>
	5	1994-021299	WO	A1	1994-09-29	Medinvent		<input type="checkbox"/>
	6	1994-025080	WO	A1	1994-11-10	Mass. Institute of Technology & Children's Medical		<input type="checkbox"/>
	7	1996-039464	WO	A1	1996-12-12	C.R. Bard, Inc.		<input type="checkbox"/>
	8	1998-023226	WO	A1	1998-06-04	Regents of the Univ. of California		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10599980
Filing Date		2007-04-03
First Named Inventor	Roland REINER	
Art Unit	1623	
Examiner Name	Ganapathy KRISHNAN	
Attorney Docket Number	067802-5008-US	

9	1998-052543	WO	A1	1998-11-26	Massachusetts Institute of Technology et al.		<input type="checkbox"/>
10	2000-009566	WO	A1	2000-02-24	Ulrich ZIMMERMANN et al.		<input type="checkbox"/>
11	2002-041928	WO	A1	2002-05-30	Assistance Publique - Hopitaux de Paris et al.		<input type="checkbox"/>
12	2002-076523	WO	A2	2002-10-03	Scimed Life Systems, Inc.		<input type="checkbox"/>
13	2003-072155	WO	A1	2003-09-04	Encelle, Inc. et al.		<input type="checkbox"/>
14	2003-082359	WO	A1	2003-10-09	Boston Scientific Limited et al.		<input type="checkbox"/>
15	2004-069294	WO	A1	2004-08-19	Assistance Publique - Hopitaux de Paris et al.		<input type="checkbox"/>
16	2005-105167	WO	A1	2005-11-10	Cellmed AG et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button **Add**

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	ATALA et al. - Endoscopic Treatment of Vesicoureteral Reflux with a Chondrocyte-Alginate Suspension - Abstract - Journal of Urology August 1994 - Number 152 (2 Pt 2) - Pages 641-643 - Discussion 644 - 1 page - NCBI Sequence Viewer - PubMed ID 8021988 - National Library of Medicine - USA	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599980
Filing Date	2007-04-03
First Named Inventor	Roland REINER
Art Unit	1623
Examiner Name	Ganapathy KRISHNAN
Attorney Docket Number	067802-5008-US

2	BENT et al. - Treatment of Intrinsic Sphincter Deficiency Using Autologous Ear Chondrocytes as a Bulking Agent - Neurourology and Urodynamics - 2001 - pages 157-165 - Volume 20 - Number 2 - Wiley-Liss, Inc. - USA	<input type="checkbox"/>
3	CLAYTON et al. - The Effect of Capsule Composition on the Biocompatibility of Alginate-Poly-1-Lysine Capsules - Journal of Microencapsulation - April/June 1991 - pages 221-233 - Volume 8 - Number 2 - Taylor & Francis Ltd - United Kingdom	<input type="checkbox"/>
4	DRAGET et al. - Alginates from Algae - Polysaccharides and Polyamides in the Food Industry. Properties, Prodyction, and Patents - 2005 - pages 1-30 - WILEY-VCH Verlag GmbH & Co. KGaA - Weinheim - Germany	<input type="checkbox"/>
5	ERTESVÅG et al. - Mannuronan C-5-Epimerases and Their Application for in Vitro and in Vivo Design of New Alginates Useful in Biotechnology - Metabolic Engineering - July 1999 - pages 262-269 - Volume 1 - Number 3 - Academic Press - Available online at http://www.ideallibrary.com - USA	<input type="checkbox"/>
6	JORK et al. - Biocompatible Alginate from Freshly Collected Laminaria Pallida for Implanation - Journal of Applied Microbiology and Biotechnology - February 2000 - pages 224-229 - Volume 53 - Number 2 - Springer-Verlag - USA and Germany	<input type="checkbox"/>
7	LI et al. - Reexamining the Egg-Box Model in Calcium-Alginate Gels with X-Ray Diffraction - Biomacromolecules - February 2007 - pages 464-468 - Volume 8 - Number 2 - American Chemical Society - USA	<input type="checkbox"/>
8	MANOJLOVIC et al. - Immobilization of Cells by Electrostatic Droplet Generation: A Model System for Potential Application in Medicine - Original Research - International Journal of Nanomedicine - 2006 - pages 163-171 - Volume 1 - Number 2 - Dove Medical Press Limited - United Kingdom	<input type="checkbox"/>
9	MARLER et al. - Soft-Tissue Augmentation with Injectable Alginate and Syngeneic Fibroblasts - Plastic and Reconstructive Surgery - Journal of the American Society of Plastic Surgeons - May 2000 - pages 2049-2058 - Volume 105 - Number 6 - USA	<input type="checkbox"/>
10	SPERGER et al. - Analysis of Composition, Molecular Weight, and Water Content Variations in Sodium Alginate Using Solid-State NMR Spectroscopy - Journal of Pharmaceutical Sciences - August 2011 - pages 3441-3452 - Volume 100 - Number 8 - Published online on March 31, 2011 in Wiley Online Library (wileyonlinelibrary.com) DOI 10.1002/jps.2252 - Wiley-Liss, Inc. and the American Pharmacists Association - USA	<input type="checkbox"/>
11	XU et al. - Preparation of the Soft Tissue Bulking Agent Composed of Calcium Alginate Microspheres and Its Resorption in Vito - Chinese Journal of Biomedical Engineering - October 2004 - pages 448-454 - Volume 23 - Number 5 - English Abstract - Page 454 - China	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599980
Filing Date	2007-04-03
First Named Inventor	Roland REINER
Art Unit	1623
Examiner Name	Ganapathy KRISHNAN
Attorney Docket Number	067802-5008-US

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599980
Filing Date	2007-04-03
First Named Inventor	Roland REINER
Art Unit	1623
Examiner Name	Ganapathy KRISHNAN
Attorney Docket Number	067802-5008-US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/H. Janice Lee/	Date (YYYY-MM-DD)	2012-02-16
Name/Print	H. Janice Lee	Registration Number	64,526

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.